These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

91 related items for PubMed ID: 1617626

  • 21. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ, Yang J, Shu S, Rosenberg SA.
    J Immunol; 1986 May 15; 136(10):3899-909. PubMed ID: 2871106
    [Abstract] [Full Text] [Related]

  • 22. Activation of nonspecific killer cells by interleukin 2-containing supernatants.
    Teh HS, Yu M.
    J Immunol; 1983 Oct 15; 131(4):1827-33. PubMed ID: 6194216
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Antitumor protection from the murine T-cell leukemia/lymphoma EL4 by the continuous subcutaneous coadministration of recombinant macrophage-colony stimulating factor and interleukin-2.
    Vallera DA, Taylor PA, Aukerman SL, Blazar BR.
    Cancer Res; 1993 Sep 15; 53(18):4273-80. PubMed ID: 8364923
    [Abstract] [Full Text] [Related]

  • 26. Systemic treatment with n-6 polyunsaturated fatty acids attenuates EL4 thymoma growth and metastasis through enhancing specific and non-specific anti-tumor cytolytic activities and production of TH1 cytokines.
    Salem ML.
    Int Immunopharmacol; 2005 Jun 15; 5(6):947-60. PubMed ID: 15829411
    [Abstract] [Full Text] [Related]

  • 27. Indomethacin modulation of adriamycin-induced effects on multiple cytolytic effector functions.
    Maccubbin DL, Cohen SA, Ehrke MJ.
    Cancer Immunol Immunother; 1990 Jun 15; 31(6):373-80. PubMed ID: 2386983
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Studies on the mechanisms of action of the immunomodulator Bestatin in various screening test systems.
    Schorlemmer HU, Bosslet K, Dickneite G, Lüben G, Sedlacek HH.
    Behring Inst Mitt; 1984 May 15; (74):157-73. PubMed ID: 6383322
    [Abstract] [Full Text] [Related]

  • 30. Studies on macrophage-activating factor (MAF) in antitumor immune responses. I. Tumor-specific Lyt-1+2- T cells are required for producing MAF able to generate cytolytic as well as cytostatic macrophages.
    Nakajima H, Fujiwara H, Takai Y, Izumi Y, Sano S, Tsuchida T, Hamaoka T.
    J Immunol; 1985 Sep 15; 135(3):2199-205. PubMed ID: 3894520
    [Abstract] [Full Text] [Related]

  • 31. Immunomodulation by various nitrosoureas and its effect on the survival of the murine host bearing a syngeneic tumor.
    Nagarkatti M, Toney DM, Nagarkatti PS.
    Cancer Res; 1989 Dec 01; 49(23):6587-92. PubMed ID: 2573418
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Retrovirus-mediated immunosuppression. I. FeLV-UV and specific FeLV proteins alter T lymphocyte behavior by inducing hyporesponsiveness to lymphokines.
    Orosz CG, Zinn NE, Olsen RG, Mathes LE.
    J Immunol; 1985 May 01; 134(5):3396-403. PubMed ID: 2984289
    [Abstract] [Full Text] [Related]

  • 35. Studies on the cytolytic attack mechanism of the cytotoxic T lymphocyte (CTL): preparation of antisera against cellfree cytosolic extracts of a CTL clone capable of blocking the lethal hit stage of CTL cytolysis and analysis of the cytolytic structure.
    Hiserodt JC.
    J Immunol; 1985 Jul 01; 135(1):53-62. PubMed ID: 3158707
    [Abstract] [Full Text] [Related]

  • 36. Involvement of doxorubicin-induced Fas expression in the antitumor effect of doxorubicin on Lewis lung carcinoma in vivo.
    Yoshimoto Y, Kawada M, Ikeda D, Ishizuka M.
    Int Immunopharmacol; 2005 Feb 01; 5(2):281-8. PubMed ID: 15652759
    [Abstract] [Full Text] [Related]

  • 37. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts.
    Gabrilovich DI, Ciernik IF, Carbone DP.
    Cell Immunol; 1996 May 25; 170(1):101-10. PubMed ID: 8665590
    [Abstract] [Full Text] [Related]

  • 38. Local conditions in the host influence immunotherapy with interleukin-2 and LAK cells.
    Steller EP, Ottow RT, Eggermont AM, Marquet RL, Sugarbaker PH.
    Cancer Detect Prev; 1988 May 25; 12(1-6):81-90. PubMed ID: 3263202
    [Abstract] [Full Text] [Related]

  • 39. Selective modulation by alpha-difluoromethylornithine of T-lymphocyte and antibody-mediated cytotoxic responses to mouse tumor allografts.
    Ehrke MJ, Porter CW, Eppolito C, Mihich E.
    Cancer Res; 1986 Jun 25; 46(6):2798-803. PubMed ID: 3084078
    [Abstract] [Full Text] [Related]

  • 40. In vivo adriamycin-induced apoptosis in peritoneal murine macrophages: partial participation of a caspase cascade.
    Domínguez-Rodríguez JR, Chaparro-Huerta V, Hernández-Flores G, Gómez-Contreras PC, Lerma-Dáz JM, Ortiz-Lazareno PC, Cervantes-Munguia R, Orbach-Arbouys S, Scott-Algara D, Cuellar AB.
    Anticancer Res; 2004 Jun 25; 24(5A):2689-96. PubMed ID: 15517873
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.